Alexey V. Rayevsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexey V. Rayevsky has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Pashenko
Enamine (Ukraine)
1 shared publication - Alexandre Varnek
Laboratory of Chemoinformatics, UMR 7140 CNRS, University of Strasbourg, 4, rue B. Pascal, Strasbourg, France, 67000
1 shared publication - Andrii S. Poturai
Enamine (Ukraine)
1 shared publication - Diana Alieksieieva
Enamine Ltd., Winston Churchill Street 78, Kyïv 02094, Ukraine
1 shared publication - Dmitriy M. Volochnyuk
Institute of Organic Chemistry, National Academy of Sciences of Ukraine, 5 Akademik Kuhar Street, 02660 Kyiv, Ukraine
1 shared publication - Dragos Horvath
University of Strasbourg
1 shared publication
Latest Publications
- Open Access
In Vitro Evaluation of In Silico Screening Approaches in Search for Selective ACE2 Binding Chemical Probes
New models for ACE2 receptor binding, based on QSAR and docking algorithms were developed, using XRD structural data and ChEMBL 26 database hits as training sets. The selectivity of the potential ACE2-binding ligands towards Neprilysin (NEP) and ACE was evaluated. The Enamine screening collection (3.2 million compounds) was virtually screened according to the above models, in order to find possible ACE2-chemical probes, useful for the study of SARS-CoV2-induced neurological disorders. An enzymology inhibition assay for ACE2 was optimized, and the combined diversified set of predicted selective ACE2-binding molecules from QSAR modeling, docking, and ultrafast docking was screened in vitro. The in vitro hits included two novel chemotypes suitable for further optimization.
Open AccessIn Vitro Evaluation of In Silico Screening Approaches in Search for Selective ACE2 Binding Chemical Probes
New models for ACE2 receptor binding, based on QSAR and docking algorithms were developed, using XRD structural data and ChEMBL 26 database hits as training sets. The selectivity of the potential ACE2-binding ligands towards Neprilysin (NEP) and ACE was evaluated. The Enamine screening collection (3.2 million compounds) was virtually screened according to the above models, in order to find possible ACE2-chemical probes, useful for the study of SARS-CoV2-induced neurological disorders. An enzymology inhibition assay for ACE2 was optimized, and the combined diversified set of predicted selective ACE2-binding molecules from QSAR modeling, docking, and ultrafast docking was screened in vitro. The in vitro hits included two novel chemotypes suitable for further optimization.